TERNS PHARMACEUTICALS INC (TERN) Forecast, Price Target & Analyst Ratings
NASDAQ:TERN • US8808811074
41.925 USD
-0.9 (-2.09%)
Last: Mar 9, 2026, 10:32 AM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for TERNS PHARMACEUTICALS INC (TERN).
Forecast Snapshot
Consensus Price Target
$55.08
+ 31.38% Upside
Next Earnings Forecast
Release DateMar 31, 2026
PeriodQ4 / 2025
EPS Estimate-$0.30
Revenue Estimate
ChartMill Buy Consensus
85.56%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$55.08
Upside
+ 31.38%
From current price of $41.93 to mean target of $55.08, Based on 18 analyst forecasts
Low
$17.17
Median
$57.63
High
$73.50
Price Target Revisions
1 Month
0.83%
3 Months
77.37%
Price Target Summary
18 analysts have analysed TERN and the average price target is 55.08 USD. This implies a price increase of 31.38% is expected in the next year compared to the current price of 41.925.
The average price target has been revised upward by 77.37% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
85.56%
TERN was analyzed by 18 analysts. The buy percentage consensus is at 86. So analysts seem to be very confident about TERN.
In the previous month the buy percentage consensus was at a similar level.
TERN was analyzed by 18 analysts, which is quite many. So the average rating should be quite meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-12-11 | Citizens | Maintains | Market Outperform -> Market Outperform |
| 2025-12-09 | Mizuho | Maintains | Outperform -> Outperform |
| 2025-12-09 | BMO Capital | Maintains | Outperform -> Outperform |
| 2025-12-09 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-12-09 | Barclays | Maintains | Overweight -> Overweight |
| 2025-12-09 | Truist Securities | Maintains | Buy -> Buy |
| 2025-12-09 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-11-26 | Citizens | Maintains | Market Outperform -> Market Outperform |
| 2025-11-25 | Barclays | Maintains | Overweight -> Overweight |
| 2025-11-19 | Truist Securities | Maintains | Buy -> Buy |
| 2025-11-18 | BMO Capital | Maintains | Outperform -> Outperform |
| 2025-11-13 | Mizuho | Maintains | Outperform -> Outperform |
| 2025-11-11 | Barclays | Maintains | Overweight -> Overweight |
| 2025-11-04 | BMO Capital | Maintains | Outperform -> Outperform |
| 2025-11-04 | Barclays | Maintains | Overweight -> Overweight |
| 2025-11-04 | Truist Securities | Reiterate | Buy -> Buy |
| 2025-11-04 | HC Wainwright & Co. | Upgrade | Neutral -> Buy |
| 2025-11-03 | William Blair | Upgrade | Market Perform -> Outperform |
| 2025-10-23 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2025-10-22 | Barclays | Maintains | Overweight -> Overweight |
| 2025-10-15 | Truist Securities | Initiate | Buy |
| 2025-09-17 | Barclays | Initiate | Overweight |
| 2025-05-13 | BMO Capital | Maintains | Outperform -> Outperform |
| 2025-04-21 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2025-02-28 | William Blair | Initiate | Market Perform |
Next Earnings Forecast Details
Next Earnings Details
Release DateMar 31, 2026
PeriodQ4 / 2025
EPS Estimate-$0.30
Revenue Estimate
Revenue Q2QN/A
EPS Q2Q-23.28%
Number of Analysts14
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
0.35%
EPS (3 Months)
3.31%
Next Earnings Summary
TERN is expected to report earnings on 3/31/2026. The consensus EPS estimate for the next earnings is -0.3 USD and the consensus revenue estimate is 0 USD.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 1M | -100.00% | 3.281M | 59.064M 1,700.18% | 267.72M 353.27% | 343.32M 28.24% | 713.04M 107.69% | 1.107B 55.25% | ||||||||
| EBITDA YoY % growth | -70M -280.64% | -36.64M 47.66% | -49.35M -34.69% | -64.25M -24.72% | -104.478M -66.15% | -105.06M 0.70% | -112.742M -11.02% | -135.836M -20.48% | -167.76M -23.50% | -182.07M -8.53% | -162.792M 10.59% | 46.104M 128.32% | 204.82M 344.26% | 897.5M 338.19% | 1.793B 99.78% | |
| EBIT YoY % growth | -70.2M -280.28% | -37.03M 47.25% | -49.86M -34.65% | -64.802M -24.41% | -135.246M -65.34% | -105.442M 0.67% | -115.722M -13.60% | -138.015M -19.26% | -164.807M -19.41% | -174.357M -5.79% | -267.057M -53.17% | -111.623M 58.20% | 85.315M 176.43% | 430.77M 404.92% | 779.71M 81.00% | |
| Operating Margin | N/A | N/A | -4,986.00% | N/A | N/A | N/A | N/A | N/A | N/A | -5,314.16% | -452.15% | -41.69% | 24.85% | 60.41% | 70.43% | |
| EPS YoY % growth | N/A | N/A | -2.34 28.53% | -1.92 21.79% | -1.36 30.60% | -1.23 11.02% | -1.10 2.67% | -1.22 -10.94% | -1.55 -27.32% | -1.63 -5.06% | -1.59 2.50% | -0.63 60.26% | 0.59 193.02% | 4.06 590.13% | 6.58 62.06% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | Q1 / 28 | Q2 / 28 | Q3 / 28 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.30 -23.28% | -0.28 -7.14% | -0.31 -18.87% | -0.34 -25.94% | -0.37 -24.22% | -0.35 -24.50% | -0.36 -15.51% | -0.35 -1.99% | -0.35 5.64% | -0.34 2.94% | -0.34 5.71% | -0.34 2.94% |
| Revenue Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |||||
| EBITDA Q2Q % growth | -30.206M -17.86% | -32.354M -18.20% | -32.509M -19.01% | -32.708M -18.35% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -32.04M -23.47% | -32.334M -17.89% | -34.2M -24.90% | -35.369M -27.61% | -41.269M -28.81% | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
-11.19%
EPS Next 5 Year
-7.09%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
-16.74%
EBIT Next 5 Year
-9.07%
TERNS PHARMACEUTICALS INC / TERN Forecast FAQ
What do analysts expect the price target to be for TERNS PHARMACEUTICALS INC (TERN)?
18 analysts have analysed TERN and the average price target is 55.08 USD. This implies a price increase of 31.38% is expected in the next year compared to the current price of 41.925.
When does TERNS PHARMACEUTICALS INC (TERN) report earnings?
TERNS PHARMACEUTICALS INC (TERN) will report earnings on 2026-03-31, after the market close.
What are the consensus estimates for TERNS PHARMACEUTICALS INC (TERN) next earnings?
The consensus EPS estimate for the next earnings of TERNS PHARMACEUTICALS INC (TERN) is -0.3 USD and the consensus revenue estimate is 0 USD.
Can you provide the consensus rating for TERNS PHARMACEUTICALS INC stock?
The consensus rating for TERNS PHARMACEUTICALS INC (TERN) is 85.5556 / 100 . This indicates that analysts generally have a positive outlook on the stock.